

Wright Medical Group, Inc.
Pro Forma Sales Growth Information
(unaudited)

	First Quarter 2014 Pro Forma Constant Currency Sales Growth ⁽¹⁾	Second Quarter 2014 Pro Forma Constant Currency Sales Growth ⁽¹⁾
U.S.		
Foot and Ankle	10%	11%
Upper Extremity	(11%)	(16%)
Biologics	2%	0%
Other	85%	(40%)
Total U.S.	7%	4%
International		
Foot and Ankle	31%	(1%)
Upper Extremity	11%	59%
Biologics	45%	8%
Other	(10%)	(50%)
Total International	26%	2%
Global		
Foot and Ankle	15%	7%
Upper Extremity	(3%)	9%
Biologics	12%	2%
Other	10%	(47%)
Total Sales	12%	4%

(1) Pro Forma Constant Currency Sales Growth is calculated as the growth of 2014 actual sales, excluding the impact of foreign currency over 2013 pro forma sales (as defined and reconciled below).

Wright Medical Group, Inc.
Pro Forma Same Day Sales Growth Information
(unaudited)

	First Quarter 2014 Pro Forma Same Day Sales Growth ⁽¹⁾	Second Quarter 2014 Pro Forma Same Day Sales Growth ⁽¹⁾
U.S.		
Foot and Ankle	8%	12%
Upper Extremity	(13%)	(15%)
Biologics	0%	2%
Other	82%	(39%)
Total U.S.	5%	6%

(1) Pro Forma Same Day Sales Growth is calculated as the growth of 2014 sales per selling day over 2013 pro forma sales (as defined and reconciled below) per selling day. The U.S. selling days in Q1 2013 and Q2 2013 were 62 and 64, respectively. The U.S. selling days in Q1 2014 and Q2 2014 were 63 and 63, respectively.

Wright Medical Group, Inc.
Pro Forma Sales⁽¹⁾
(unaudited)

Q1 2013

	As Reported	Acquired	Pro Forma
U.S.			
Foot and Ankle	27,762	2,328	30,090
Upper Extremity	4,114	-	4,114
Biologics	10,453	479	10,932
Other	432	124	556
Total U.S.	42,761	2,931	45,692
International			
Foot and Ankle	7,315	2,380	9,695
Upper Extremity	1,948	583	2,531
Biologics	3,204	45	3,249
Other	1,065	987	2,052
Total International	13,532	3,995	17,527
Global			
Foot and Ankle	35,077	4,708	39,785
Upper Extremity	6,062	583	6,645
Biologics	13,657	524	14,181
Other	1,497	1,111	2,608
Total Sales	56,293	6,926	63,219

Q2 2013

	As Reported	Acquired	Pro Forma
U.S.			
Foot and Ankle	26,958	3,721	30,679
Upper Extremity	4,473	-	4,473
Biologics	10,381	684	11,065
Other	828	182	1,010
Total U.S.	42,640	4,587	47,227
International			
Foot and Ankle	10,358	2,350	12,708
Upper Extremity	1,614	673	2,287
Biologics	4,710	48	4,758
Other	1,250	1,209	2,459
Total International	17,932	4,280	22,212
Global			
Foot and Ankle	37,316	6,071	43,387
Upper Extremity	6,087	673	6,760
Biologics	15,091	732	15,823
Other	2,078	1,391	3,469
Total Sales	60,572	8,867	69,439

(1) Acquired sales represent sales recorded by Biotech, Solana and OrthoPro prior to our acquisition of those businesses. Pro Forma sales are calculated by Acquired sales to our reported revenues in each respective period of 2013.

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2014		June 30, 2014	
	International	Total	International	Total
	Net Sales	Net Sales	Net Sales	Net Sales
Net sales, as reported	\$ 23,021	\$ 72,364	\$ 45,132	\$ 143,426
Currency impact as compared to prior period	(429)	(429)	(458)	(458)
Net sales, excluding the impact of foreign currency	\$ 22,592	\$ 71,935	\$ 44,674	\$ 142,968

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2014	June 30, 2013	June 30, 2014	June 30, 2013
Operating Income				
Operating loss, as reported	\$ (29,171)	\$ (13,181)	\$ (52,217)	\$ (26,407)
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	615	195	1,219	302
Total	615	195	1,219	302
<i>Reconciling items impacting Selling, General and Administrative expense:</i>				
Distributor conversions	51	334	156	691
Transition costs - OrthoRecon divestiture	1,296	2,623	3,545	2,623
Due diligence, transaction and transition costs - acquisitions ⁽¹⁾	4,592	1,446	9,745	8,943
Total	5,939	4,403	13,446	12,257
<i>Reconciling items impacting Amortization of Intangible Assets:</i>				
Amortization of distributor non-competes	627	717	1,064	1,547
Operating loss, as adjusted	\$ (21,990)	\$ (7,866)	\$ (36,488)	\$ (12,301)
Operating loss, as adjusted, as a percentage of net	(30.4)%	(13.0)%	(25.4)%	(10.5)%

(1) For the three months ended March 31, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2014	June 30, 2013	June 30, 2014	June 30, 2013
EBITDA				
Net loss, as reported	\$ (53,583)	\$ (15,539)	\$ (83,881)	\$ (20,457)
Interest expense, net	4,172	3,990	8,308	7,935
Provision (benefit) for income taxes	1,970	(6,209)	(10,200)	(12,613)
Depreciation	4,599	3,503	8,840	6,949
Amortization of intangible assets	2,675	2,778	4,862	4,384
EBITDA	(40,167)	(11,477)	(72,071)	(13,802)
<i>Reconciling items impacting EBITDA</i>				
Non-cash stock-based compensation expense ⁽¹⁾	3,778	2,892	6,098	4,505
Other expense (income), net	18,270	4,577	33,556	(1,272)
Inventory step-up amortization	615	195	1,219	302
Distributor conversions	51	334	156	691
Due diligence, transaction and transition costs	5,888	4,069	13,290	11,566
Adjusted EBITDA	\$ (11,565)	\$ 590	\$ (17,752)	\$ 1,990
Adjusted EBITDA as a percentage of net sales	(16.0)%	1.0 %	(12.4)%	1.7 %

- (1) For the six months ended June 30, 2013, amount excludes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options, which is included in due diligence, transaction and transition costs.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2014	June 30, 2013	June 30, 2014	June 30, 2013
Net Income				
Loss before taxes, as reported	\$ (51,613)	\$ (21,748)	\$ (94,081)	\$ (33,070)
<i>Pre-tax impact of reconciling items:</i>				
Inventory step-up amortization	615	195	1,219	302
Distributor conversion and non-competes	678	1,051	1,220	2,238
Non-cash interest expense on 2017 Convertible Notes	2,295	2,152	4,554	4,269
Derivatives mark-to-market adjustment	—	(1,000)	1,000	1,000
Transition costs - OrthoRecon divestiture	1,296	2,623	3,545	2,623
Due diligence, transaction and transition costs ⁽¹⁾	4,592	1,446	9,745	8,943
CVR mark-to-market adjustments	18,499	5,840	32,794	5,840
Gain on previously held investment in BioMimetic	—	—	—	(7,798)
Loss before taxes, as adjusted	(23,638)	(9,441)	(40,004)	(15,653)
Provision (benefit) for income taxes, as reported	\$ 1,970	\$ (6,209)	\$ (10,200)	\$ (12,613)
U.S. tax impact resulting from gain in discontinued operations	(1,646)	—	10,716	—
Inventory step-up amortization	—	76	—	118
Distributor conversion and non-competes	—	410	—	874
Non-cash interest expense on 2017 Convertible Notes	—	855	—	1,673
Derivatives mark-to-market adjustment	—	(378)	—	400
Transaction and transition costs - OR divestiture	—	1,025	—	1,025
Due diligence, transaction and transition costs	—	565	—	2,003
Provision (benefit) for income taxes, as adjusted	\$ 324	\$ (3,656)	\$ 516	\$ (6,520)
Effective tax rate, as adjusted	(1.4)%	38.7%	(1.3)%	41.7%
Net loss, as adjusted	\$ (23,962)	\$ (5,785)	\$ (40,520)	\$ (9,133)
Weighted-average number of shares outstanding-diluted	49,640	46,234	49,135	43,849
Net loss from continuing operations, as adjusted, per diluted share	\$ (0.48)	\$ (0.13)	\$ (0.82)	\$ (0.21)

(1) For the six months ended June 30, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Six Months Ended	
	June 30, 2014	June 30, 2013	June 30, 2014	June 30, 2013
Net Income per Diluted Share				
Net loss from continuing operations, as reported, per diluted share	\$ (1.08)	\$ (0.34)	\$ (1.71)	\$ (0.47)
U.S. tax impact resulting from gain in discontinued operations	0.03	0.00	(0.22)	0.00
Inventory step-up amortization	0.01	0.00	0.02	0.00
Distributor conversion and non-competes	0.01	0.01	0.02	0.03
Non-cash interest expense on 2017 Convertible Notes	0.05	0.03	0.09	0.06
Derivatives mark-to-market adjustment	—	(0.01)	0.02	0.01
CVR mark-to-market adjustments	0.37	0.13	0.67	0.14
Transition costs - OrthoRecon divestiture	0.03	0.03	0.07	0.04
Due diligence, transaction and transition costs	0.09	0.02	0.20	0.17
Gain on previously held investment in BioMimetic	—	—	—	(0.19)
Net loss from continuing operations, as adjusted, per diluted share ⁽¹⁾	\$ (0.48)	\$ (0.13)	\$ (0.82)	\$ (0.21)

(1) Reconciling items may not add to total net income, as adjusted, per diluted share due to rounding differences.

Wright Medical Group, Inc.
Reconciliation of Free Cash Flow
(dollars in thousands--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2014	June 30, 2013	June 30, 2014	June 30, 2013
Net cash used in operating activities	\$ (24,350)	\$ 10,923	\$ (51,590)	\$ 5,755
Capital expenditures	(16,448)	(5,995)	(24,284)	(9,735)
Free cash flow	\$ (40,798)	\$ 4,928	\$ (75,874)	\$ (3,980)

Use of Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as pro forma sales; pro forma sales growth; net sales, excluding the impact of foreign currency; operating income, as adjusted; net income, as adjusted; EBITDA, as adjusted; net income, as adjusted, per diluted share; effective tax rate, as adjusted; and free cash flow. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. The measures

exclude such items as costs associated with distributor conversions and non-competes, non-cash interest expense related to the Company's 2017 Convertible Notes, mark-to-market adjustments on derivative assets and liabilities, mark-to-market adjustments on CVRs and impairment and other charges to write down to fair value assets and liabilities acquired in the BioMimetic acquisition, transaction and transition costs, and impacts from the sale of the OrthoRecon business, all of which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.